Mechanisms Leading to the Development of Hormone-Resistant Prostate Cancer

Urologic Clinics of North America

Volumn 33, Issue 2, 2006, Pages 201-210

  Kasper, Susan ^a   Cookson, Michael S ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; ANDROSTENEDIONE; ANTIANDROGEN; ANTINEOPLASTIC AGENT; BICALUTAMIDE; CYPROTERONE ACETATE; DIETHYLSTILBESTROL; ESTRADIOL; ESTROGEN; FLUTAMIDE; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; HYDROXYFLUTAMIDE; LIGAND; NUCLEAR RECEPTOR COACTIVATOR 2; PACLITAXEL; PRASTERONE; PROGESTERONE; REGULATOR PROTEIN; SMALL INTERFERING RNA; STEROID RECEPTOR COACTIVATOR 1;

ADVANCED CANCER; ANDROGEN DEPRIVATION THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER STEM CELL; CANCER SURVIVAL; CARCINOGENESIS; CASTRATION; CHEMOSENSITIVITY; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; EARLY INTERVENTION; GENE AMPLIFICATION; GENE MUTATION; HORMONAL REGULATION; HORMONE DEPENDENCE; HORMONE RESISTANCE; HORMONE RESPONSE; HUMAN; LETHALITY; MESENCHYME; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROSTATECTOMY; PROTEIN CONTENT; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL RATE; SURVIVAL TIME; THERAPY DELAY;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN;

EID: 33646475297     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ucl.2005.12.010     Document Type: Review

References (75)

1. Huggins C., and Hodges C.V. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1 (1941) 293-297
2. Sharifi N., Gulley J.L., and Dahut W.L. Androgen deprivation therapy for prostate cancer. JAMA 294 (2005) 238-244
3. Chang S.S., Benson M.C., Campbell S.C., et al. Society of Urologic Oncology position statement: redefining the management of hormone-refractory prostate carcinoma. Cancer 103 (2005) 11-21
4. Crawford E.D. Epidemiology of prostate cancer. Urology 62 Suppl 1 (2003) 3-12
5. Jemal A., Murray T., Ward E., et al. Cancer statistics, 2005. CA Cancer J Clin 55 (2005) 10-30
6. Ward J.F., and Moul J.W. Treating the biochemical recurrence of prostate cancer after definitive primary therapy. Clin Prostate Cancer 4 (2005) 38-44
7. The Veterans Administration Co-operative Urological Research Group. Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 124 (1967) 1011-1017
8. Byar D.P. Proceedings: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer 32 (1973) 1126-1130
9. The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. Br J Urol 79 (1997) 235-246
10. Moul J.W., Wu H., Sun L., et al. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol 171 (2004) 1141-1147
11. Messing E.M., Manola J., Sarosdy M., et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 341 (1999) 1781-1788
12. Messing E.M. Re: disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure?. J Urol 170 (2003) 1955-1956
13. Bolla M., Collette L., Blank L., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360 (2002) 103-106
14. Pilepich M.V., Caplan R., Byhardt R.W., et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol 15 (1997) 1013-1021
15. D'Amico A.V., Manola J., Loffredo M., et al. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 292 (2004) 821-827
16. Debes J.D., and Tindall D.J. Mechanisms of androgen-refractory prostate cancer. N Engl J Med 351 (2004) 1488-1490
17. Petrylak D.P. The current role of chemotherapy in metastatic hormone-refractory prostate cancer. Urology 65 Suppl (2005) 3-7
18. Feldman B.J., and Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 1 (2001) 34-45
19. Kemppainen J.A., Lane M.V., Sar M., et al. Androgen receptor phosphorylation, turnover, nuclear transport, and transcriptional activation. Specificity for steroids and antihormones. J Biol Chem 267 (1992) 968-974
20. Holzbeierlein J., Lal P., LaTulippe E., et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 164 (2004) 217-227
21. Koivisto P., Kononen J., Palmberg C., et al. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 57 (1997) 314-319
22. Linja M.J., Savinainen K.J., Saramaki O.R., et al. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 61 (2001) 3550-3555
23. Edwards J., Krishna N.S., Grigor K.M., et al. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer 89 (2003) 552-556
24. Edwards J., and Bartlett J.M. The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 1: modifications to the androgen receptor. BJU Int 95 (2005) 1320-1326
25. Stanbrough M., Leav I., Kwan P.W., et al. Prostatic intraepithelial neoplasia in mice expressing an androgen receptor transgene in prostate epithelium. Proc Natl Acad Sci USA 98 (2001) 10823-10828
26. Chen C.D., Welsbie D.S., Tran C., et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 10 (2004) 33-39
27. Gregory C.W., Johnson Jr. R.T., Mohler J.L., et al. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 61 (2001) 2892-2898
28. Veldscholte J., Ris-Stalpers C., Kuiper G.G., et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 173 (1990) 534-540
29. Tan J., Sharief Y., Hamil K.G., et al. Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol Endocrinol 11 (1997) 450-459
30. Taplin M.E., Bubley G.J., Ko Y.J., et al. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 59 (1999) 2511-2515
31. Taplin M.E., Rajeshkumar B., Halabi S., et al. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol 21 (2003) 2673-2678
32. Han G., Buchanan G., Ittmann M., et al. Mutation of the androgen receptor causes oncogenic transformation of the prostate. Proc Natl Acad Sci USA 102 (2005) 1151-1156
33. Gottlieb B., Beitel L.K., Wu J.H., et al. The androgen receptor gene mutations database (ARDB): 2004 update. Hum Mutat 23 (2004) 527-533
34. Buchanan G., Greenberg N.M., Scher H.I., et al. Collocation of androgen receptor gene mutations in prostate cancer. Clin Cancer Res 7 (2001) 1273-1281
35. Gregory C.W., He B., Johnson R.T., et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 61 (2001) 4315-4319
36. Yeh S., and Chang C. Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells. Proc Natl Acad Sci USA 93 (1996) 5517-5521
37. Miyamoto H., Yeh S., Wilding G., et al. Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells. Proc Natl Acad Sci USA 95 (1998) 7379-7384
38. Fujimoto N., Yeh S., Kang H.Y., et al. Cloning and characterization of androgen receptor coactivator, ARA55, in human prostate. J Biol Chem 274 (1999) 8316-8321
39. Culig Z., Comuzzi B., Steiner H., et al. Expression and function of androgen receptor coactivators in prostate cancer. J Steroid Biochem Mol Biol 92 (2004) 265-271
40. Culig Z., Steiner H., Bartsch G., et al. Mechanisms of endocrine therapy-responsive and -unresponsive prostate tumours. Endocr Relat Cancer 12 (2005) 229-244
41. Edwards J., and Bartlett J.M. The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 2: androgen-receptor cofactors and bypass pathways. BJU Int 95 (2005) 1327-1335
42. Debes J.D., Comuzzi B., Schmidt L.J., et al. p300 regulates androgen receptor-independent expression of prostate-specific antigen in prostate cancer cells treated chronically with interleukin-6. Cancer Res 65 (2005) 5965-5973
43. Mirosevich J., Gao N., Gupta A., et al. The expression and role of Foxa proteins in prostate cancer. Prostate (2005) In press
44. Heinlein C.A., and Chang C. Androgen receptor in prostate cancer. Endocr Rev 25 (2004) 276-308
45. Wang L., Hsu C.L., and Chang C. Androgen receptor corepressors: an overview. Prostate 63 (2005) 117-130
46. Craft N., Shostak Y., Carey M., et al. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 5 (1999) 280-285
47. Arai Y., Yoshiki T., and Yoshida O. c-erbB-2 oncoprotein: a potential biomarker of advanced prostate cancer. Prostate 30 (1997) 195-201
48. Yeh S., Lin H.K., Kang H.Y., et al. From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci USA 96 (1999) 5458-5463
49. Wen Y., Hu M.C., Makino K., et al. HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res 60 (2000) 6841-6845
50. Graff J.R., Konicek B.W., McNulty A.M., et al. Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. J Biol Chem 275 (2000) 24500-24505
51. Culig Z., Hobisch A., Cronauer M.V., et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 54 (1994) 5474-5478
52. Chan J.M., Stampfer M.J., Giovannucci E., et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279 (1998) 563-566
53. Jin R.J., Wang Y., Masumori N., et al. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice. Cancer Res 64 (2004) 5489-5495
54. Cussenot O., Villette J.M., Cochand-Priollet B., et al. Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumors. Prostate Suppl 8 (1998) 43-51
55. Vashchenko N., and Abrahamsson P.A. Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities. Eur Urol 47 (2005) 147-155
56. Reya T., Morrison S.J., Clarke M.F., et al. Stem cells, cancer, and cancer stem cells. Nature 414 (2001) 105-111
57. Sell S., and Pierce G.B. Maturation arrest of stem cell differentiation is a common pathway for the cellular origin of teratocarcinomas and epithelial cancers. Lab Invest 70 (1994) 6-22
58. Isaacs J.T., and Coffey D.S. Etiology and disease process of benign prostatic hyperplasia. Prostate Suppl 2 (1989) 33-50
59. De Marzo A.M., Meeker A.K., Epstein J.I., et al. Prostate stem cell compartments: expression of the cell cycle inhibitor p27Kip1 in normal, hyperplastic, and neoplastic cells. Am J Pathol 153 (1998) 911-919
60. Rumpold H., Heinrich E., Untergasser G., et al. Neuroendocrine differentiation of human prostatic primary epithelial cells in vitro. Prostate 53 (2002) 101-108
61. Aumuller G., Leonhardt M., Janssen M., et al. Neurogenic origin of human prostate endocrine cells. Urology 53 (1999) 1041-1048
62. Kurita T., Medina R.T., Mills A.A., et al. Role of p63 and basal cells in the prostate. Development 131 (2004) 4955-4964
63. Wang Y., Hayward S., Cao M., et al. Cell differentiation lineage in the prostate. Differentiation 68 (2001) 270-279
64. Xue Y., Smedts F., Debruyne F.M., et al. Identification of intermediate cell types by keratin expression in the developing human prostate. Prostate 34 (1998) 292-301
65. Collins A.T., Habib F.K., Maitland N.J., et al. Identification and isolation of human prostate epithelial stem cells based on alpha(2)beta(1)-integrin expression. J Cell Sci 114 (2001) 3865-3872
66. Hudson D.L., O'Hare M., Watt F.M., et al. Proliferative heterogeneity in the human prostate: evidence for epithelial stem cells. Lab Invest 80 (2000) 1243-1250
67. Huss W.J., Gray D.R., Greenberg N.M., et al. Breast cancer resistance protein-mediated efflux of androgen in putative benign and malignant prostate stem cells. Cancer Res 65 (2005) 6640-6650
68. Thiery J.P. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2 (2002) 442-454
69. Grunert S., Jechlinger M., and Beug H. Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nat Rev Mol Cell Biol 4 (2003) 657-665
70. Gotzmann J., Mikula M., Eger A., et al. Molecular aspects of epithelial cell plasticity: implications for local tumor invasion and metastasis. Mutat Res 566 (2004) 9-20
71. Garrod D., Chidgey M., and North A. Desmosomes: differentiation, development, dynamics and disease. Curr Opin Cell Biol 8 (1996) 670-678
72. Wijnhoven B.P., Dinjens W.N., and Pignatelli M. E-cadherin-catenin cell-cell adhesion complex and human cancer. Br J Surg 87 (2000) 992-1005
73. Perl A.K., Wilgenbus P., Dahl U., et al. A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature 392 (1998) 190-193
74. Kwok W.K., Ling M.T., Lee T.W., et al. Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target. Cancer Res 65 (2005) 5153-5162
75. Veveris-Lowe T.L., Lawrence M.G., Collard R.L., et al. Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells. Endocr Relat Cancer 12 (2005) 631-643